An outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been an especially challenging threat to international public health.1,2 We and others have shown the prevalence of gastrointestinal (GI) symptoms in patients infected with SARS-CoV-2.3, 4, 5 Current evidence suggests that two host proteins are important for SARS-CoV-2 infection in vitro: receptor angiotensin converting enzyme 2 (ACE2) for cell entry and transmembrane serine protease 2 (TMPRSS2) for viral Spike protein (S) priming.6 However, whether the mechanism of GI tract injury in patients with coronavirus disease 2019 (COVID-19) is viral direct infection or inflammatory response is still controversial. To understand how ACE2 and TMPRSS2 cause viral GI infection and correlate with GI symptoms in patients with COVID-19, it is important to compare host receptor expression patterns and localization in GI tissues. In this study, we comprehensively investigated the expression and co-localization of ACE2, TMPRSS2, SARS-CoV-2 NP, and severity of inflammation in GI tissues from 19 COVID-19 patients with GI symptoms and explored their associations with GI symptoms.